Literature DB >> 25146265

The cancer drug that almost wasn't.

Ken Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25146265     DOI： 10.1126/science.345.6199.865

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  9 in total

1.  Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.

Authors:  Navjotsingh Pabla; Alice A Gibson; Mike Buege; Su Sien Ong; Lie Li; Shuiying Hu; Guoqing Du; Jason A Sprowl; Aksana Vasilyeva; Laura J Janke; Eberhard Schlatter; Taosheng Chen; Giuliano Ciarimboli; Alex Sparreboom
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

2.  CDK6 is a regulator of stem cells "Egr" to wake up.

Authors:  Monica L Guzman
Journal:  Blood       Date:  2015-01-01       Impact factor: 22.113

Review 3.  Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis.

Authors:  Kyrillus S Shohdy; Shaimaa Lasheen; Loay Kassem; Omar Abdel-Rahman
Journal:  Ther Adv Drug Saf       Date:  2017-08-08

Review 4.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

5.  First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.

Authors:  Jack McCain
Journal:  P T       Date:  2015-08

Review 6.  Targeting CDK4 and CDK6: From Discovery to Therapy.

Authors:  Charles J Sherr; David Beach; Geoffrey I Shapiro
Journal:  Cancer Discov       Date:  2015-12-11       Impact factor: 39.397

7.  Restoration of tumor suppressor functions by small-molecule inhibitors.

Authors:  Slovénie Pyndiah; Daitoku Sakamuro
Journal:  Mol Cell Oncol       Date:  2015-01-23

8.  Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.

Authors:  J Y Chan; K LaPara; D Yee
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

9.  Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.

Authors:  Yu Sun; Ye Sun; Kun Yan; Zhuxuan Li; Cheng Xu; Yibo Geng; Changcun Pan; Xin Chen; Liwei Zhang; Qiaoran Xi
Journal:  EBioMedicine       Date:  2019-05-03       Impact factor: 8.143
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.